For Immediate Release
Quest Diagnostics Acquires Pathway Diagnostics to Expand Biomarker and Oncology Testing
December 9, 2008
Cleveland, OH and Malibu, CA -- Quest Diagnostics is pleased to announce the acquisition of Pathway Diagnostics, a specialized provider of biomarker assay development, validation, and testing services, located in Malibu, CA. Pathway Diagnostics, a CAP and CLIA-certified laboratory, offers a broad portfolio of customized biomarkers, companion diagnostics, and proprietary assays with concentration in infectious diseases, cardio-respiratory, central nervous system and tissue-based oncology testing.
The acquisition of Pathway Diagnostics provides Quest Diagnostics with an extensive biomarker offering, supported by a global network of standardized clinical trials central laboratories. The combined capabilities of Nichols Institute including Specialty Laboratories, and now Pathway Diagnostics, further strengthens Quest Diagnostics Clinical Trials’ position as a world leader in biomarker services.
Quest Diagnostics’ test menu will expand in the areas of immunoassay development, anatomic pathology, flow cytometry, circulating tumor cell analyses, and molecular genetic assays. Pathway’s expertise in cytokine multiplexing, HIV testing, and immunohistochemistry will enhance Quest Diagnostics’ capabilities to partner with Pharma to develop novel companion diagnostics.
“We are delighted to offer Pharma companies comprehensive support in biomarker testing for all phases of clinical trials” according to Dr. Michael Harvey, Managing Director, Quest Diagnostics Clinical Trials. “The customized assay development services available through Pathway will further strengthen our early-phase development capabilities”.
Quest Diagnostics Clinical Trials operates central laboratory facilities in the United States, United Kingdom and India, a project management facility in Wavre, Belgium, and alliance relationships with laboratories in Singapore, Australia, and China.
“This exciting development underscores our commitment to provide pharmaceutical companies with the scientific innovation and consultative expertise needed to incorporate novel biomarkers into clinical study protocols” says Dr. Mary Hall Gregg, Vice President Quest Diagnostics Clinical Trials and International.
Quest Diagnostics Clinical Trials is a leading provider of central laboratory testing, bioinformatics, and other services that enable Pharmaceutical and Biotechnology companies to accelerate the drug development process. The company offers unsurpassed esoteric diagnostic testing services and interpretive consultation through its international network of laboratories and its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care worldwide. Additional company information is available www.questcentralabs.com.
Print this release.
